Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

H. E. Lessner, S. Valenstein, R. Kaplan, P. DeSimone, A. Yunis

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

Original languageEnglish (US)
Pages (from-to)1359-1361
Number of pages3
JournalCancer treatment reports
Volume64
Issue number12
StatePublished - 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II study of L-asparaginase in the treatment of pancreatic carcinoma'. Together they form a unique fingerprint.

Cite this